podcast.de
Anmeldung
Anmeldung Registrierung
Auto Hell Dunkel
Erweiterte Suche
  1. Startseite
  2. Podcasts
  3. BiocompCHATibility Podcast

Episoden

Dieser Podcast wird gerade aktualisiert – wir suchen nach neuen Episoden …

Navigating Biocompatibility in Early Feasibility Studies

23 Minuten
In this episode of NAMSA’s BiocompCHATibility Podcast, our hosts discuss early feasibility studies and the scope of biocompatibility necessary to get started. They highlight the importance of controlling device response in a small patient group and how this approach shapes biocompatibility considerations within the framework of risk management.

“The control measure of just having a few patients is definitely used as a reason why, in part Biocompatibility doesn't need to be as extensive as it needs to be for a pivotal where you have hundreds of people and commercialization where you lose practically all control.” – Don Pohl

“I want to make sure I'm choosing materials that I can support in my plan that I know have a general knowledge of safety.” – Sheri Krajewski

“There's no specific guidance that tells you what you have to do in terms of testing and what you don't, but the concept is you're going to creep up on everything you'll do. You'll do some biocomp for early feasibility.” – Don Pohl

Key Discussion Points:

Crafting a dynamic biological safety plan that evolves over time

Establishing a robust evaluation strategy from the beginning to prevent missing important tests later

Designing studies for high-risk cardiovascular implants and the importance of addressing biocompatibility and safety concerns

Exploring Equivalency in Biocompatibility

40 Minuten
n this episode of NAMSA’s BiocompCHATibility podcast, we welcome back Dr. Phil Smiraldo (Principal Toxicologist, NAMSA) for his third appearance as an honorary host. The discussion centers on the complexities of equivalency in biocompatibility, examining how equivalency can range from simple to complex and how a predicate device does not always equal equivalency.

Listen in as we explore these topics with Dr. Smiraldo and gain insights into the intricate world of biocompatibility and the challenges faced when trying to establish equivalence between medical devices.

 

“The world of equivalency runs the spectrum from incredibly simple to probably way too complex.” – Don Pohl

“When we do these types of extractions on, we'll say prior devices and change to device, we're going to have variability within our experiments.” – Phil Smiraldo

“You know whether you call it an equivalency assessment or change control assessment. Whatever you want to call it, I mean [10993] part one tells us if there's a change, you have to evaluate it.” – Don Pohl

“I guess long story short, you could theoretically go through this whole exercise and end up with the two devices that are equivalent from a systemic toxicity perspective and that's it.” – Phil Smiraldo 

Key Discussion Points

Importance of confirming identical materials of construction, device categorization, and the IFU to ensure that the device remains equivalent

The detailed process required to establish proof of equivalence

The critical role of adhering to standards in biocompatibility assessments

Chemistry with the MFDS

35 Minuten
In this episode, our hosts are joined by Charles Ducker, PhD (NAMSA's Senior Director of Analytical Services) who recently returned from Korea, where he provided training to the MFDS (Ministry of Food and Drug Safety) about ISO 10993-18. Throughout this discussion, we review the use of the standard and how it is adopted by Korean authorities. We also explore the challenges that lie ahead for device developers and testing labs.

“I think they [MFDS] were maybe surprised at the complexity. Laying out the information you have on your materials and the knowledge that you already have that may not lead to doing testing.” – Dr. Charles Ducker

“They were interested in how to apply ISO 10993-1 and how you apply ISO 10993-18 to the standard. And they want to know how to assess whether a laboratory has conducted the test appropriately.” – Dr. Charles Ducker

“One of the things I thought was very interesting… around Part 18, was what is different now versus the outdated version, and what changes came about. We had a lot of discussion about what is required and one of the big ones was AET [Analytical Evaluation Threshold] and how we calculate it.” – Dr. Charles Ducker

“Also, about how we qualify methods, what components go into that and what data you have to have behind the scenes to support the fact that your methods are appropriate for the intended use.” – Dr. Charles Ducker

Topics include:

Korea’s current position with the use of ISO 10993-18

Qualification of a laboratory for chemical characterization testing

Solvents and temperatures, and the justifications for each

New FDA Biocompatibility Guidance – Let’s Discuss

38 Minuten
On the latest installment of the BiocompCHATibility podcastis episode, our hosts are joined by Dr. Phil Smiraldo for his third feature3-peat episode on the podcast.

The conversation throughout this episode focuses and we discuss on the new recently published FDA biocompatibility guidance document —issued onn September 7, 2023.

“My favorite nuance is that annex A has slightly been updated because now the X’s and O’s are almost all gone.” – Don Pohl

“Of these materials, you touch them every day, and your clothes are made out of them... Why would we need to do biocompatibility testing as a device? At a high level, that is what [(Attachment G)] says.” – Don Pohl

“There are a few caveats, such as devices made for neonates… they are going to want to see the data. And similar type wording for pregnant woman.” – Phil Smiraldo

“We are not saying it’s never possible, but you’re going to have to really convince us if you only look at Part 1 and not our guidance” – Sheri Krajewski-Bibins

“One thing that I do like about this FDA document is it uses the same language from the ISO 10993 series.” – Phil Smiraldo

Discussion points include:

Verbiage updates to legally market devices and the fineprint.

The Addition of Appendix G and how it can be utilized.

A general overview of other changes by the FDA from their previous document.

Welcome to the RA QA Café

32 Minuten
In this first BiocompCHATibility Podcast episode of 2023, our hosts are happy to introduce

a new podcast to the NAMSA family, and talk a little bit to the hosts about the insightful

topics to come.

This new, conversational podcast will feature a new set of hosts who dedicate each

episode to trending regulatory and quality affairs topics within the MedTech industry.

Future topics include:

Refuse to Accept Policy for 510(k)s – This episode will delve into the procedures

and criteria FDA intends to use in assessing whether a premarket notification

(510(k)) submission meets a minimum threshold of acceptability and if it should

be accepted for substantive review.

FDA Releases Draft Guidance: Content of Premarket Submissions for Device

Software Functions – As a follow-up to one of NAMSA’s recent blog posts, our

hosts will describe information that the FDA deems important during its

evaluation of the safety and effectiveness of device software with one or more

device functions.

Compliance Pitfalls (Start-up Focus) – This episode will focus on common

compliance obstacles faced when dealing with documenting procedures,

complaint handling processes, supplier controls, audit & training, laboratory

controls, monitoring and calibration and more.
Alle Folgen ansehen (38)
In Podcasts werben
Schalte jetzt Werbung in Podcasts.

Über diesen Podcast

BiocompCHATibility Podcast, Presented by NAMSA Unforeseen challenges and roadblocks are often present when managing and conducting medical device biological safety programs. Join NAMSA for a first-of-its-type podcast series, “BiocompCHATibility,” as each episode features leading industry experts and discussion on how to proactively address specific medical device evaluation scenarios, regulatory expectations and new testing methodologies.
Urheberangabe
Copyright 2019 All rights reserved.
Letzter Check
vor 6 Tg.
Zuerst veröffentlicht
vor 5 J.
Podcast melden

„BiocompCHATibility“

Worum geht es? Danach fragen wir noch nach dem Grund.

Abonnenten

Jd
jddvelwe

Teilen

Mein Archiv

Deine Privatkopie der Folgen, die du nicht verlieren willst.

Podcast-Folgen verschwinden. Feeds werden auf die letzten Episoden gekürzt, Hoster räumen alte Dateien ab, Formate wechseln den Anbieter und lassen ihr Archiv zurück. Mit „Mein Archiv“ sichert podcast.de die Folgen deiner Podcasts für dich — angefangen bei den ältesten, denn die sind zuerst weg.

  • Deine gesicherten Folgen bleiben hörbar, auch wenn das Original offline geht.
  • Auch Folgen, die im heutigen Feed gar nicht mehr stehen — podcast.de kennt sie noch.
  • Herunterladen bleibt möglich, solange die Folge beim Podcaster liegt. Der zählt seine Abrufe wie bisher.
Startet bald

Sei beim Start von Mein Archiv dabei

Mein Archiv ist fast fertig. Trag dich ein, dann bekommst du eine E-Mail, sobald es losgeht – und bist von Anfang an dabei. Wir schreiben dir nur zum Start, keine Werbung, keine Weitergabe deiner Daten.

Du bekommst zuerst eine Bestätigungsmail. Abmelden geht jederzeit. Datenschutz